Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a
company focused on developing, marketing, and selling multiple
men's health and wellness products through a secure telemedicine
platform, including its uniquely formulated erectile dysfunction
(ED) drug, "Mango,", is pleased to announce the upcoming filming of
a TV interview as part of a Multi-Part TV Series on FMW Media's
"New To The Street" business TV show featuring CEO, Jacob Cohen,
which will air on Fox Business Network, Bloomberg TV (as a
sponsored program) and NewsMax TV (through its syndicated and
sponsored networks).
On Monday July 10th, 2023, Jane King, the host
of "New To The Street", will sit down with Mr. Cohen to discuss the
rapidly growing men’s health and wellness market, learn more about
the Company’s current Mango ED products, and explore the Company’s
plans for both the near term and long term future. This interview
will the first of a three-part series and will be aired on the Fox
Business Network, Bloomberg TV (as sponsored program) and NewsMax
TV (through its syndicated and sponsored networks).
“I’m excited for the opportunity to sit down
with renowned host and journalist, Jane King, to share more about
the dramatic strides we have been making at MangoRx as well as the
exciting path we see ahead of us,” commented Jacob Cohen, CEO and
Co-Founder of Mangoceuticals, Inc. “We have accomplished so much in
such a short period of time, and we have some big steps just ahead
as the health, wellness, and direct-to-consumer telemedicine
industry continues to experience rapid growth. This interview will
also allow me to share more about the upcoming release of our
second Mango ED product, which leverages Sildenafil—the active
ingredient found in Viagra™—alongside our existing custom compound
of Oxytocin and L-Arginine, as well as our plans to introduce
additional products into the marketplace.”
The Interview will be filmed at the Nasdaq
MarketSite Studio in Times Square and exact dates and air times of
the interview will be made available and released shortly after the
interview has been completed.
About Mango
Created using a special formulation featuring
the same active ingredient as in Cialis™ (Tadalafil), each part of
the Mango formulation plays a critical role in helping men achieve
optimum performance. We believe the key to our success lies in our
unique blend of ingredients, which are used in U.S. Food and Drug
Administration (“FDA”) approved drugs. Mango contains a combination
of Tadalafil, Oxytocin, and L-Arginine that have been traditionally
used to treat sexual dysfunction.
Mango is a prescription medication that must be
approved by a physician. After an individual has completed an
online telehealth visit, our network of medical providers will
review and approve a prescription if medically appropriate. Mango
is a rapidly dissolved tablet (RDT) that is absorbed orally. For
best results, we advise taking Mango at least 15 minutes before
engaging in sexual activity. Tadalafil, one of the main ingredients
in Mango, typically has effects that last up to 36 hours.
About Mangoceuticals
Mangoceuticals, Inc. is a company focused on
developing, marketing, and selling a variety of men's health and
wellness products and services via a secure telemedicine platform.
To date, the Company has identified men's wellness telemedicine
services and products as a growing sector and especially related to
the area of erectile dysfunction (ED). The Company has developed a
new brand of ED product under the brand name "Mango" (think "Man
Go"). For more information, please visit www.MangoRx.com.
Cautionary Note Regarding
Forward-Looking StatementsCertain statements made in this
press release contain forward-looking information within the
meaning of applicable securities laws, including within the meaning
of the Private Securities Litigation Reform Act of 1995
("forward-looking statements"). These forward-looking statements
represent the Company's current expectations or beliefs concerning
future events and can generally be identified using statements that
include words such as "estimate," "expects," "project," "believe,"
"anticipate," "intend," "plan," "foresee," "forecast," "likely,"
"will," "target" or similar words or phrases. These forward-looking
statements are subject to risks, uncertainties and other factors,
many of which are outside of the Company's control which could
cause actual results to differ materially from the results
expressed or implied in the forward-looking statements, including,
but not limited to; our ability to obtain additional funding and
generate revenues to support our operations; risks associated with
our ED product which have not been, and will not be, approved by
the U.S. Food and Drug Administration ("FDA") and have not had the
benefit of the FDA's clinical trial protocol which seeks to prevent
the possibility of serious patient injury and death; risks that the
FDA may determine that the compounding of our planned products does
not fall within the exemption from the Federal Food, Drug, and
Cosmetic Act ("FFDCA Act") provided by Section 503A; risks
associated with related party relationships and agreements; the
effect of data security breaches, malicious code and/or hackers;
competition and our ability to create a well-known brand name;
changes in consumer tastes and preferences; material changes and/or
terminations of our relationships with key parties; significant
product returns from customers, product liability, recalls and
litigation associated with tainted products or products found to
cause health issues; our ability to innovate, expand our offerings
and compete against competitors which may have greater resources;
our significant reliance on related party transactions; the
projected size of the potential market for our technologies and
products; risks related to the fact that our Chairman and Chief
Executive Officer, Jacob D. Cohen, has majority voting control over
the Company; risks related to the significant number of shares in
the public float, our share volume, the effect of sales of a
significant number of shares in the marketplace, and the fact that
the majority of our shareholders paid less for their shares than
the public offering price of our common stock in our recent initial
public offering; the fact that we have a significant number of
outstanding warrants to purchase shares of common stock at $1.00
per share, the resale of which underlying shares have been
registered under the Securities Act of 1933, as amended; our
ability to build and maintain our brand; cybersecurity, information
systems and fraud risks and problems with our websites; changes in,
and our compliance with, rules and regulations affecting our
operations, sales, marketing and/or our products; shipping,
production or manufacturing delays; regulations we are required to
comply with in connection with our operations, manufacturing,
labeling and shipping; our dependency on third-parties to prescribe
and compound our ED product; our ability to establish or maintain
relations and/or relationships with third-parties; potential safety
risks associated with our Mango ED product, including the use of
ingredients, combination of such ingredients and the dosages
thereof; the effects of high inflation, increasing interest rates
and economic downturns, including potential recessions, as well as
macroeconomic, geopolitical, health and industry trends, pandemics,
acts of war (including the ongoing Ukraine/Russian conflict) and
other large-scale crises; our ability to protect intellectual
property rights; our ability to attract and retain key personnel to
manage our business effectively; our ability to maintain the
listing of our common stock on the Nasdaq Capital Market; overhang
which may reduce the value of our common stock; volatility in the
trading price of our common stock; and general consumer sentiment
and economic conditions that may affect levels of discretionary
customer purchases of the Company's products, including potential
recessions and global economic slowdowns. Although we believe that
our plans, intentions and expectations reflected in or suggested by
the forward-looking statements we make in this release are
reasonable, we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties.
More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended March 31, 2023. These
filings are available at www.sec.gov and at our website at
https://investors.mangorx.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mangoceuticals
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals https://twitter.com/mango_rx
https://www.facebook.com/MangoRxOfficial
Or just click here to see why Orange is the new
Bluehttps://www.mangorx.com
FOR INVESTOR RELATIONSFraxon
Market Initiatives, LLCFrank BenedettoPhone: 619-915-9422Email:
investors@mangorx.com
MEDIA CONTACTPhoenix MGMT
Marketing & Consultinginfo@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Sep 2023 to Sep 2024